退伍军人前列腺癌患者ADT后后续治疗时间的种族差异
该回顾性人群研究分析了2001-2021年退伍军人健康系统中141,495例仅接受ADT的前列腺癌患者,发现非西班牙裔黑人、西班牙裔和其他种族患者后续治疗率均显著低于非西班牙裔白人(HR分别为0.82、0.93、0.91),且年轻患者中差异更强。
要点
- 非西班牙裔黑人ADT后后续治疗率显著低于非西班牙裔白人(HR=0.82)。
- 西班牙裔和其他种族后续治疗率也较低(HR=0.93和0.91)。
- 年龄分层后,种族与后续治疗时间的关联在年轻患者中更强。
核心结论
- 所有受检种族相比非西班牙裔白人,一线ADT后后续治疗率均显著更低,年轻患者尤甚。
- 需进一步研究明确后续治疗率低反映的是进展率低还是进展患者治疗不足。
研究设计与样本
- 回顾性人群分析,数据来自退伍军人事务医疗系统。
- 纳入2001-2021年接受ADT单药治疗的141,495例前列腺癌患者。
- 主要结局为从ADT单药至后续治疗的时间,后续治疗包括ARPI、NSAA、化疗或其他治疗。
- 采用Cox竞争风险模型和Kaplan-Meier分析,调整基线协变量。
主要发现
- 中位随访51.1个月(IQR 22.8-97.2)期间,28,144例(20%)接受后续治疗。
- 后续治疗中ARPI 11,319例(40%),NSAA 12,990例(46%),化疗3,402例(12%),其他二线治疗433例(2%)。
- 非西班牙裔黑人相比非西班牙裔白人后续治疗率显著更低(HR=0.82,95%CI 0.80-0.85)。
- 西班牙裔(HR=0.93,95%CI 0.88-0.98)和其他男性(HR=0.91,95%CI 0.84-0.98)后续治疗率也较低。
- 按年龄分层,种族/族裔与后续治疗时间的关联在年轻患者中更强。
临床怎么用
- 临床中应关注接受ADT单药治疗的前列腺癌患者,尤其少数族裔和年轻患者,是否存在后续治疗不足。
- 需个体化评估疾病进展与治疗时机,避免因种族差异导致治疗延迟。
局限性
- 回顾性研究设计可能引入残留混杂。
- 未明确后续治疗率低是否反映真实进展率差异或治疗不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For metastatic and certain advanced prostate cancer (PC), guidelines support intensified androgen deprivation therapy (ADT) as first-line (1 L) systemic treatment. However, some patients receive ADT alone, leading to tumor progression requiring 2nd line therapy. Despite racial disparities in PC outcomes, there are no population-level studies assessing racial differences in time to subsequent treatment after 1 L ADT. METHODS: We performed a retrospective population-level analysis to assess the association between race and time to subsequent treatment after ADT in the Veterans Affairs Health Care System. Primary outcome was time from ADT monotherapy to subsequent treatment, defined as receipt of androgen receptor pathway inhibitor (ARPI), non-steroidal first-generation anti-androgen (NSAA), chemotherapy, or other treatments. We used Cox competing risks models and Kaplan-Meier (KM) analyses to estimate subsequent treatment rates by Non-Hispanic White [NHW], Non-Hispanic Black [NHB], Hispanic and Other patients, adjusted for baseline covariates. RESULTS: From 2001-2021, 141,495 PC patients received ADT alone. During median (IQR) follow-up of 51.1 (22.8, 97.2) months, 28,144 patients (20%) had subsequent treatment: 11,319 (40%) ARPIs, 12,990 (46%) NSAAs, 3402 (12%) chemotherapy and 433 (2%) other 2nd line therapies. NHB had significantly lower subsequent treatment rates (HR = 0.82, 95% CI = 0.80-0.85) vs. NHW. Both Hispanic (HR = 0.93, 95%CI = 0.88-0.98) and Other men (HR = 0.91, 95%CI = 0.84-0.98), also had lower subsequent treatment rates. When stratified by age, associations between race/ethnicity and time to subsequent treatment were stronger in younger patients. CONCLUSIONS: All races examined had significantly lower rates of subsequent treatment after 1 L ADT relative to NHW, especially in younger patients. Further investigation is needed to determine if these lower rates of subsequent treatment reflect lower rate of progression or undertreatment of progressing patients.
引用
- Friedrich NA, Janes JL, Parrish J, et al. Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer. Prostate Cancer Prostatic Dis. 2025. PMID: 40615515. doi:10.1038/s41391-025-00995-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。